Literature DB >> 17328722

The changing global epidemiology of Acinetobacter baumannii infections: a development with major public health implications.

M E Falagas1, E A Karveli2.   

Abstract

Acinetobacter baumannii infections have become increasingly common among critically-ill patients in intensive care units (ICUs) worldwide. A. baumannii clinical isolates are frequently resistant to most antimicrobial agents and evidence of pan-drug resistance among A. baumannii isolates (i.e., resistance to all available antimicrobial agents, including polymyxins) has been reported. These facts constitute an alarming development in the field of infectious diseases, with major public health implications. More intensive efforts are urgently required to elucidate the epidemiological and infection control issues related to these organisms and to improve the management of patients with such infections.

Entities:  

Mesh:

Year:  2007        PMID: 17328722     DOI: 10.1111/j.1469-0691.2006.01596.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  26 in total

1.  Clonal diversity of nosocomial epidemic Acinetobacter baumannii strains isolated in Spain.

Authors:  Pilar Villalón; Sylvia Valdezate; Maria J Medina-Pascual; Virginia Rubio; Ana Vindel; Juan A Saez-Nieto
Journal:  J Clin Microbiol       Date:  2010-12-22       Impact factor: 5.948

2.  The K1 capsular polysaccharide of Acinetobacter baumannii strain 307-0294 is a major virulence factor.

Authors:  Thomas A Russo; Nicole R Luke; Janet M Beanan; Ruth Olson; Shauna L Sauberan; Ulrike MacDonald; L Wayne Schultz; Timothy C Umland; Anthony A Campagnari
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

3.  Next-Generation Sequencing and Comparative Analysis of Sequential Outbreaks Caused by Multidrug-Resistant Acinetobacter baumannii at a Large Academic Burn Center.

Authors:  Hajime Kanamori; Christian M Parobek; David J Weber; David van Duin; William A Rutala; Bruce A Cairns; Jonathan J Juliano
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

4.  Current advances and challenges in the development of Acinetobacter vaccines.

Authors:  Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

5.  Complete genome sequence and phylogenetic analysis of nosocomial pathogen Acinetobacter nosocomialis strain NCTC 8102.

Authors:  Bindu Subhadra; Surya Surendran; Bo Ra Lim; Jong-Sung Yim; Dong Ho Kim; Kyungho Woo; Kyudong Han; Man Hwan Oh; Chul Hee Choi
Journal:  Genes Genomics       Date:  2019-06-08       Impact factor: 1.839

Review 6.  Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

Authors:  Brad Spellberg; George Talbot
Journal:  Clin Infect Dis       Date:  2010-08-01       Impact factor: 9.079

7.  Characterization of epidemiologically unrelated Acinetobacter baumannii isolates from four continents by use of multilocus sequence typing, pulsed-field gel electrophoresis, and sequence-based typing of bla(OXA-51-like) genes.

Authors:  Ahmed Hamouda; Benjamin A Evans; Kevin J Towner; Sebastian G B Amyes
Journal:  J Clin Microbiol       Date:  2010-04-26       Impact factor: 5.948

8.  A prospective evaluation of synergistic effect of sulbactam and tazobactam combination with meropenem or colistin against multidrug resistant Acinetobacter baumannii.

Authors:  Mohammed Ali M Marie; Lakshmana Gowda Krishnappa; Alhusain J Alzahrani; Murad A Mubaraki; Abdullah A Alyousef
Journal:  Bosn J Basic Med Sci       Date:  2015-10-14       Impact factor: 3.363

9.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

10.  Identification and characterization of an Acinetobacter baumannii biofilm-associated protein.

Authors:  Thomas W Loehfelm; Nicole R Luke; Anthony A Campagnari
Journal:  J Bacteriol       Date:  2007-11-16       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.